key: cord-0026112-6y5cz34u
authors: Zheng, Yu; Sun, Hao; Mei, Yong; Gao, Yongxia; Lv, Jinru; Pan, Dijia; Wang, Lu; Zhang, Xintong; Hu, Deliang; Sun, Feng; Li, Wei; Zhang, Gang; Zhang, Huazhong; Chen, Ying; Wang, Shenrui; Zhang, Zhongman; Li, Baoquan; Chen, Xufeng; Zhang, Jinsong; Lu, Xiao
title: Can Cardiopulmonary Rehabilitation Facilitate Weaning of Extracorporeal Membrane Oxygenation (CaRe-ECMO)? Study Protocol for a Prospective Multidisciplinary Randomized Controlled Trial
date: 2022-01-07
journal: Front Cardiovasc Med
DOI: 10.3389/fcvm.2021.779695
sha: f234f7c82689ef0f94be4b49c20285b94ebc8b44
doc_id: 26112
cord_uid: 6y5cz34u

Background: Mortality of patients suffering from critical illness has been dramatically improved with advanced technological development of extracorporeal membrane oxygenation (ECMO) therapy. However, the majority of ECMO-supported patients failed to wean from ECMO therapy. As one of several options, cardiopulmonary rehabilitation serves as effective intervention in the improvement of cardiovascular and respiratory function in various major critical illness. Nonetheless, its role in facilitating ECMO weaning has not yet been explored. The purpose of this study is to investigate the effectiveness of cardiopulmonary rehabilitation on rate of ready for ECMO weaning in ECMO-supported patients (CaRe-ECMO). Methods: The CaRe-ECMO trial is a randomized controlled, parallel group, clinical trial. This trial will be performed in a minimum number of 366 ECMO-supported eligible patients. Patients will be randomly assigned to either: (1) the CaRe-ECMO group, which will be treated with usual care including pharmacotherapy, non-pharmacotherapy, and specific nursing for ECMO therapy and the CaRe-ECMO program; or (2) the control group, which will receive usual care only. The CaRe-ECMO program consists of protocolized positioning, passive range of motion (PROM) training, neuromuscular electrical stimulation (NMES), surface electrical phrenic nerve stimulation (SEPNS), and pulmonary rehabilitation. The primary outcome of the CaRe-ECMO trial is the rate of ready for ECMO weaning at CaRe-ECMO day 7 (refers to 7 days after the CaRe-ECMO program initiation). Secondary outcomes include rate of ECMO and mechanical ventilation weaning, total length in day of ready for ECMO weaning, ECMO weaning and mechanical ventilation, all-cause mortality, rate of major post-ECMO complications, ECMO unit length of stay (LOS) and hospital LOS, total cost for hospitalization, cerebral performance category (CPC), activities of daily living (ADL), and health-related quality of life (HRQoL). Discussion: The CaRe-ECMO is designed to answer the question “whether cardiopulmonary rehabilitation can facilitate weaning of ECMO (CaRe-ECMO).” Should the implementation of the CaRe-ECMO program result in superior primary and secondary outcomes as compared to the controls, specifically the add-on effects of cardiopulmonary rehabilitation to the routine ECMO practice for facilitating successful weaning, the CaRe-ECMO trial will offer an innovative treatment option for ECMO-supported patients and meaningfully impact on the standard care in ECMO therapy. Clinical Trial Registration: ClinicalTrials.gov, identifier: NCT05035797.

Recent improvements in technology have created extra chances for lifesaving, i.e., using extracorporeal membrane oxygenation (ECMO) as a bridge to win over time for the body and medical strategies struggling with critical illness (1) . Patients with acute cardiac, pulmonary, or cardiopulmonary failure who have failed conventional treatment appeared to benefit from ECMO therapy (2) . However, this population is often exposed to prolonged immobilization, which may lead to multiple complications and impaired physical function (3) . Shortening the sedative course and managing issues such as intensive care unit (ICU)-acquired weakness and critical illness-induced cardiopulmonary function impairment should take priority, as this can greatly impact the post-ECMO prognosis. In this context, attention toward enhancing ICU recovery, reducing complications, and improving functional prognosis has started to be shifted to ECMOsupported patients (4) . Upon this perspective, early rehabilitation is recommended to be applied in this population.

The general aim of early rehabilitation for critical illness is to improve or maintain cardiopulmonary function, which encounters the requirement of ECMO-supported patients (5) . There is a variety of early rehabilitation techniques that may benefit patients with critical illness (6) . However, due to the huge difficulties in the application of early rehabilitation in ECMOsupported patients, only a few evidence has been published (4, 7) . Considering their pathophysiological condition, regardless of venovenous ECMO (VV-ECMO) or venoarterial ECMO (VA-ECMO), cardiopulmonary rehabilitation is hypothesized to compensate cardiopulmonary function of patients and consequently speed up the recovery process after the emergency period (normally after 72 h) (8) . For instance, cardiac output and maximal oxygen uptake were proven to increase after one subtype of cardiopulmonary rehabilitation in intubated, sedated patients confined to bed in the ICU (9) .

Upon the above rationale, the upcoming question is that what benefits of cardiopulmonary rehabilitation can be delivered to ECMO-supported patients. For clinicians, ECMO weaning is particularly challenging and annual ECMO mortality has been reported to be approximately ranged 40-70% (10, 11) . According to our experience, delayed ECMO weaning also demonstrated worse functional prognosis and impaired health-related quality of life (HRQoL). Previous studies have documented that rate of mechanical ventilation weaning was improved in patients received early rehabilitation intervention, while its effectiveness in ECMO weaning remains unclear (12) . Indeed, the successful weaning of ECMO is complex and multifactorial (13) . ECMO weaning at the earliest possible time would be expected to improve outcomes, reduce cost, and optimize functional prognosis (14) . This inspires us to hypothesize that if the medical rationale is based on its assumed benefits on cardiac function and oxygenation, then cardiopulmonary rehabilitation may subsequently contribute to earlier weaning of ECMO. Our perspective is to provide solutions with the application of cardiopulmonary rehabilitation and convert the aforementioned physiological changes (e.g., increased cardiopulmonary function) into patient-oriented outcomes (e.g., earlier weaning of ECMO and increased rate of ECMO weaning).

Considering the limited evidence in this aspect, ongoing innovation must move from guessing to exploring the effectiveness of cardiopulmonary rehabilitation through an adequately powered trial. Therefore, we design this multidisciplinary randomized controlled trial (RCT) to answer the following clinical question-can cardiopulmonary rehabilitation facilitate weaning of ECMO (CaRe-ECMO)? The results of this trial may subsequently provide innovative treatment solution, specifically the add-on effects of cardiopulmonary rehabilitation to the routine clinical practice for further successful weaning of ECMO.

The CaRe-ECMO trial is a pragmatic, multidisciplinary, randomized controlled, parallel group, clinical trial. Table 1 shows the overview of the trial registration information. The trial protocol was developed according to the Consolidated Standards of Reporting Trials (CONSORT) statements for pragmatic trials and non-pharmacological treatment interventions (15, 16) . 

The consolidated criteria for patient enrollment are those:

(1) aged 18 years or older; (2) eligible for receiving ECMO (VV or VA) therapy; (3) with mechanical ventilation; (4) with stable condition and eligible for cardiopulmonary rehabilitation after 72 h of ECMO; (5) with no contraindications for cardiopulmonary rehabilitation; (6) not pregnant; (7) with a life expectancy of more than 3 days; (8) wean from ECMO therapy within the first 3 days before the initiation of the CaRe-ECMO program; (9) not use ECMO as a bridge to recovery or definitive treatment (e.g., lung transplantation or heart transplantation); (10) not enrolled in another trial previously; and (11) sign informed consent form by the guardian (18). According to previously published guidelines, the specific indications and contraindications for VV-ECMO and VA-ECMO are given in Tables 2, 3 , respectively (19, 20) . Patients will be withdrawn from the trial if: (1) the guardian makes such a request with no reasons; (2) the patient develops adverse events due to cardiopulmonary rehabilitation (e.g., rib fracture, limb fracture); and (3) the patient develops ECMOrelated complications (e.g., bleeding, thromboembolism, severe infection) and is ever unsuitable for participating in the trial according to the point of view by clinicians.

Eligible patients who meet the eligibility criteria and are provided with ECMO therapy in our Department of Emergency Medicine will be enrolled in the CaRe-ECMO trial. Their guardians will receive a detailed explanation of trial purpose and procedures. The patients will have a same chance to be randomly assigned to the CaRe-ECMO group or the control group. They also will be informed that they have the right to withdraw from the trial at any time of the trial period.

Simple randomization (1:1) will be applied using a computer generated random sequence, which will be independently administered and concealed by the Clinical Research Board from the School of Public Health of Nanjing Medical University (from here on called allocation center). Once a patient has been deemed eligible and the informed consent form has been signed, an independent trial assistant will register the participant, record her/his group allocation, and reveal the group allocation to those delivering the interventions (21) . Figure 1 demonstrates the overview of the recruitment, randomization, and allocation based on the CONSORT principle. 

Patients in the CaRe-ECMO group will be treated with usual care, ECMO therapy, and cardiopulmonary rehabilitation program. Usual care normally comprises pharmacotherapy, mechanical ventilation, continuous renal replacement therapy (CRRT), intra-aortic balloon pump (IABP), and specific nursing for ECMO therapy and their original injuries, as appropriate. In addition, patients will receive cardiopulmonary rehabilitation from a multidisciplinary team (e.g., clinicians, rehabilitation physicians, nurses, and therapists) who were fully trained to provide care to every ECMO-supported patient when medically appropriate. A core group of clinicians and therapists (e.g., XL, ZS, XC, YZ, YC, and SW) are competent in the use of a screening procedure (e.g., stability of hemodynamic and vital signs, stability of blood coagulation, stability of homeostasis, stability of mechanical ventilation, stability of ECMO flows, and stability of cannulation position and tightness) to determine appropriateness and safety for cardiopulmonary rehabilitation delivery according to the experience from the University of Maryland Medical Center (4). Detailed daily eligibility screening flowchart for cardiopulmonary rehabilitation is shown in Figure 2 . Once the patients pass the screen, the therapists will proceed to provide protocolized cardiopulmonary rehabilitation program, which encompasses five evidence-based components according to literature review: (1) positioning; (2) passive range of motion (PROM) training; (3) neuromuscular electrical stimulation (NMES); (4) surface electrical phrenic nerve stimulation (SEPNS); (5) respiratory proprioceptive neuromuscular facilitation (PNF) techniques; and (6) airway clearance techniques (22) (23) (24) . Detailed content and protocol are given in Table 4 . It should be emphasized that hemodynamic and vital signs, ECMO flows, and cannulation position and tightness will be continuously monitored during each rehabilitation session. In case any adverse events occur, cardiopulmonary rehabilitation session will be discontinued. Corresponding reasons for discontinuous and exact length of therapy will be recorded. After randomized treatment, the primary outcome will be assessed at the CaRe-ECMO day 7 after last cardiopulmonary rehabilitation session. All the patients who are not responded (e.g., failure in fulfilling the criteria of ready for ECMO weaning and need continuous ECMO support), regardless of trial assignment, will be provided with open-label treatment of cardiopulmonary rehabilitation. Corresponding secondary Detailed procedure of the CaRe-ECMO program is shown in Figure 3 .

No additional rehabilitation intervention, except usual care and ECMO therapy, will be provided to patients in the control group.

The primary outcome of the CaRe-ECMO trial is the rate of ready for ECMO weaning at CaRe-ECMO day 7. It means that rate of ready for ECMO weaning will be calculated 7 days after cardiopulmonary rehabilitation delivery. Checklists to define ready for ECMO weaning (hereafter called ready for ECMO weaning checklists), either for VV-ECMO or VA-ECMO, have been prepared according to literature review and shown in Tables 5, 6 (20, 28). A fixed medical staff will be responsible for checkouts of listed items daily. Eligible patients defined as ready for ECMO weaning reveal the fulfillment of all the items in the checklists. Date of ready for ECMO weaning will be recorded and the rate of ready for ECMO weaning at CaRe-ECMO day 7 will be calculated.

Secondary outcomes are listed and elaborated as follows:

1) Rate of ECMO weaning will be calculated according to date of ECMO weaning fulfilled. 2) Total length of ready for ECMO weaning refers to exact length in day till patients fulfill all the criteria of ready for ECMO weaning according to daily checkout records (14) .

3) Total length of ECMO weaning refers to exact length in day for patients treated with ECMO therapy (29) . 4) Rate of mechanical ventilation weaning will be calculated according to date of mechanical ventilation weaning fulfilled. Daily screening of mechanical ventilation weaning will be strictly performed with checklist shown in Table 7 according to the American Thoracic Society and the American College of Chest Physicians Clinical Practice Guideline (30). 5) Total length of mechanical ventilation refers to exact length in day for patients treated with mechanical ventilation. 6) All-cause mortality is defined as rate of death due to any causes and will be calculated according to date of death (31). 7) Rate of major post-ECMO complications refers to rate of complications occurred after ECMO including but not limited to ECMO-related complications (e.g., thromboembolism), mechanical ventilation-related complications (e.g., pneumonia), newly developed myocardial infarction, acute kidney injury, neurologic events (e.g., stroke, seizures), and multiple organ failure (32) . Information of major post-ECMO complications will be collected in the Complication Recording Sheet ( Table 8) . 8) Diaphragmatic thickness and mobility refer to ultrasoundguided evaluation of diaphragmatic thickness and mobility under M-mode (33). 9) Extracorporeal membrane oxygenation unit LOS accounts for length in day for stay of patients in the ICU unit. 10) Total hospital LOS accounts for total hospital LOS in day for stay of patients in both the ECMO unit and other departments. 11) Total cost for hospitalization will be calculated by addition of the cost of all the units and department admission. 12) Cerebral performance category will be recorded, for those successfully weaning of ECMO, to reflect post-ECMO neurological status (34) .

13) Activities of daily living will be evaluated, for those successfully weaning of ECMO, with Katz Index (35) . 

Move forward to the nest step when the former step is fulfilled, should all of the steps be fulfilled indication the patient is ready for ECMO weaning

Step 1

The primary disease has been controlled or improved pulmonary function assessment: Step 2 Cardiac function assessment: If MAP > 70 mmHg, the heart rate increases over 20% of the baseline following the reduction of ECMO flow, then move to the next step

Step 3 Organ function and tissue perfusion assessment: If lactate < 2 mmol/L, SvO 2 > 70%, no symptoms of respiratory distress and improved function of other damaged organs, then move to the next step

Step 4 Patient must tolerate a full weaning trial: If disconnect oxygen supply of the ECMO with no reduction of ECMO flow, observation for 6 h, monitoring the patient to maintain parameters mentioned in Step 1-3, then move to the next step

Step 5 If

Step 1, 2, 3, and 4 are validated then the patient is under minimal ECMO support: Be sure that there is no CO 2 retention and the patient can maintain normal oxygenation and normocarbia, and FiO 2 reaches 21%, ECMO flow becomes 3-4L per minute and the sweep should be <1 L per minute, then move to the next step

Step 6

The patient is ready for VV-ECMO weaning VV-ECMO, venovenous extracorporeal membrane oxygenation; VT, tidal volume; FiO 2 , fraction of inspired oxygen; PEEP, positive end-expiratory pressure; PaO 2 , partial pressure of arterial oxygen; PaCO 2 , partial pressure of arterial carbon dioxide; MAP, mean arterial pressure; SvO 2 , mixed venous oxygen saturation.

14) Health-related quality of life will be measured, for those successfully weaning of ECMO, with SF-12 (36) .

Data in terms of rate of ready for ECMO weaning, rate of ECMO weaning, rate of mechanical ventilation weaning, allcause mortality, and rate of major post-ECMO complications will be calculated throughout the index hospitalization and followup period (e.g., CaRe-ECMO days 7, 14, 30, and 90) according to daily evaluations recorded in the medical records. Outcomes, for instance ready for ECMO weaning, will be treated as timeto-event outcomes; therefore, date and timing of events will be also recorded to facilitate statistical analysis. Total length of ready for ECMO weaning, total length in hour of ECMO weaning, total length in day of mechanical ventilation, ECMO unit LOS, and total hospital LOS will be collected according to the medical records. CPC index, ADL score, and HRQoL score will be selectively collected among those successfully weaning of ECMO across discharge day (discharge from ECMO unit) and all follow-up time points (e.g., CaRe-ECMO days 30 and 90). In addition, diaphragmatic thickness and mobility will be evaluated with ultrasound (M-mode) every 3 days for determining the allocation of phrenic nerve and the efficacy of SEPNS. The detailed data collection schedule is given in Table 9 .

Baseline demographics and clinical characteristics, directly from the medical files at randomization, will also be collected including but not limited to the following information: age, gender, main diagnosis, comorbidities (diabetes mellitus, hypertension, respiratory infection, or others), the Acute Physiology and Chronic Health Evaluation II (APACHE II) 

Move forward to the nest step when the former step is fulfilled, should all of the steps be fulfilled indicating the patient is ready for ECMO weaning

Step 1

The etiology of cardiac failure must be compatible with myocardial recovery

Step 2 Pulmonary function should not be severely impaired: If FiO 2 ≤ 50%, PEEP < 10 cmH 2 O, PIP < 30 cmH 2 O, PaO 2 > 70 mmHg, PaO 2 /FiO 2 > 200 mmHg, PaCO 2 < 45 mmHg, pH 7. 35-7.45 , no pulmonary edema in X-ray/CT scanning, then move to the next step

Step 3 Hemodynamic and cardiac functional assessment: If MAP > 70 mmHg and PPD > 30 mmHg for 24 h, the heart rate increases over 20% of the baseline following the reduction of ECMO flow, VIS of <10, LVEF of more than 40%, aortic VTI of more than 10 cm/s, decreasing trend of cTnT and BNP values, CVP < 12 cmH 2 O, lactate < 2 mmol/L, SvO 2 > 70%, with improved function of other damaged organs, then move to the next step

Step 4

The patient must tolerate a full weaning trial: Increase ACT to 200 s, then gradually reduce ECMO flow to 66% for 15 min, and then to 33% of its baseline value for 15 min, and finally a minimum of 1-1.5 L/min for 15 min. During the weaning trial, monitoring the patient to maintain parameters mentioned in Step 3

Step 5

The patient is ready for VA-ECMO weaning VA-ECMO, venoarterial extracorporeal membrane oxygenation; FiO 2 , fraction of inspired oxygen; PEEP, positive end-expiratory pressure; PIP, peak inspiratory pressure; PaO 2 , partial pressure of arterial oxygen; PaCO 2 , partial pressure of arterial carbon dioxide; MAP, mean arterial pressure; PPD, pulse pressure difference; VIS, vasoactive-inotrope score; VTI, velocity time integral; cTnT, cardiac troponin T; CVP, central venous pressure; SvO 2 , mixed venous oxygen saturation; ACT, activated clotting time. score, ECMO mode (VV-ECMO or VA-ECMO), length in hour since mechanical ventilation, partial pressure of arterial oxygen/fraction of inspired oxygen (PaO 2 /FiO 2 ) in mm Hg, positive end-expiratory pressure (PEEP), tidal volume in ml/kg of predicted body weight, respiratory rate in breaths/min, plateau pressure in cm of water, driving pressure in cm of water, arterial blood pH, PaO 2 in mm Hg, partial pressure of arterial carbon dioxide (PaCO 2 ) in mm Hg, N-terminal pro-B-type natriuretic peptide (NT-proBNP) in pg/ml, creatine kinase-MB (CK-MB) in ng/l, cardiac troponin T (cTnT) in ng/l, and ejection fraction (EF) in percentage. The above data will be recorded in the Baseline Data Collection Sheet (Table 10) . Apart from that, daily clinical monitoring for both the condition and ECMO running status of patient will be performed. The detailed information will be recorded in the Daily Monitoring Sheet (Table 11) . 

Trial assistants from the allocation center responsible for randomization will be blinded to patients in both the groups. Each cardiopulmonary rehabilitation session provided by the therapists will be sheltered with a curtain. In the control group, an optimization procedure will be imitated as closely as possible, while no cardiopulmonary rehabilitation will be provided. This action may be helpful to blind the clinicians and nurses and mitigate any bias. Assessors, data analysts, and statisticians will be blinded to group allocation.

All the data will be entered into standardized electronic case report forms (eCRFs) and stored in a bespoke trial cloud database upon its collection. Data entry will be independently performed and dated by two trial assistants. Typos and missing data will be detected by this dual-track data entry mode. When discrepancies occur, consensus will be achieved by raw-data review or discussion. Confidentiality of data is assured by restricted access to the cloud database granted to authorized investigators only, for example, members of the Data and Safety Monitoring Committee (DSMC). The primary investigators, trial coordinators, the DSMC members, data analysts, statisticians, and trial assistants will meet periodically to:

(1) monitor and review safety of patient; (2) request and perform interim data analyses; (3) review patient recruitment, accrual, and withdrawal; (4) discuss about continuing or modifying the trial; and (5) stop the trial upon any severe adverse events considered to have been caused by the CaRe-ECMO program (37) . 

We considered the rate of ready for ECMO weaning being conservatively 50% higher in the CaRe-ECMO group than in the control group at CaRe-ECMO day 7 as a clinically meaningful effect, implying a hazard ratio (HR) of 0.5. Accordingly, we performed sample size calculation for the Cox proportional hazards model with an alpha error of 5% and a power of 80%, effect size of HR = 0.5, and overall event (ready for weaning) probability of 30% at CaRe-ECMO day 7 (increases from 30 to 45%) according to our retrospective data analysis and literature review (38) . The needed sample size was estimated as n = 348, i.e., 174 per group. Due to the relative short observational period and the real-world situation (e.g., patients treated with ECMO therapy generally will not discharge till stable or death), accounting for 5% attrition according to their failing for fulfill of daily eligibility screening for cardiopulmonary rehabilitation during the therapeutic period, the target sample size is set at 366 (183 per group).

The demographic and clinical characteristics collected at randomization will be presented as means with SDs or medians with interquartile ranges for continuous variables and as percentages for categorical variables, as appropriate. For all the outcomes, we will estimate differences in effect size between the groups on both the intention-to-treat (ITT) and per protocol (PP) basis (39) . Categorical variables will be compared with the chi-square or Fisher's exact tests and continuous variables will be compared with the Student's ttest or the Wilcoxon signed-rank test, as appropriate. The time effect of day the time-to-event outcomes identified (e.g., rate of ready for ECMO weaning, rate of ECMO weaning, rate of mechanical ventilation weaning, all-cause mortality, and rate of major post-ECMO complications) between the groups will be estimated with the Cox proportional hazards regression analysis and graphically illustrated using the Kaplan-Meier methods until CaRe-ECMO days 7, 14, 30, and 90, respectively (40) . Variables, including total length of ready for ECMO weaning, total length of ECMO weaning, total length of mechanical ventilation, ECMO unit LOS, and total hospital LOS, will be treated with timeto-event data and will be analyzed with mixed-effects ordered logistic regression (41) . Secondary outcomes with normal and non-normal distributions, including CPC, ADL, HRQoL, and diaphragmatic thickness and mobility, will be estimated for group differences with mixed-effects linear regression (41) . Considering that part of patients will definitely not reach the primary endpoint, i.e., ready for ECMO weaning at CaRe-ECMO day 7 for sensitivity purpose, we will assess the heterogeneity of the treatment effect on primary outcome and secondary outcomes in pre-specified subgroups of interest as per baseline data to be collected at randomization (e.g., age, gender, main diagnosis, comorbidities, the APACHE II score, ECMO mode, length since mechanical ventilation) by using exploratory posthoc sensitivity adjusted analyses for any corresponding statistical methods mentioned above.

Interim analysis will be scheduled halfway through enrollment to check that there are no serious issues with respect to sample handling or data collection.

All the analyses will be conducted at a two-sided alpha level of 5% and will be performed using the Stata version 16 (StataCorp, College Station, Texas, USA) or other software, as appropriate.

Cardiopulmonary rehabilitation was proven to be effective in the improvement of cardiovascular and respiratory function in various major diseases (42) . However, its efficacy in ECMOsupported patients has not been well-verified. Its application in routine clinical practice always encounters a number of challenges. Specifically, one of the major barriers is the multiple sites of cannulation, which restrict the mobilization of the body. This explained why most of the trials involved patients with VV-ECMO with cannulation sites in the upper body allowing for more chances of mobilization while less on VA-ECMO (4). Nonetheless, active cardiopulmonary rehabilitation is ever difficult to be performed for various reasons. In the emergency room, patients would always be sedated with the application of nitric oxide and neuromuscular blocking agents to promote oxygenation and improve ventilator synchrony. That is why, only few studies reported results with limited sample size in awake patients with ECMO (43, 44) . Furthermore, active mobilization of the body may interrupt the ECMO flow (45) . Therefore, the upcoming challenge is to explore a cardiopulmonary rehabilitation protocol, which can be safely delivered with no interruption of the routine clinical treatment and subsequently benefit all the types of ECMO-supported patients.

Despite the fact that most of cardiopulmonary rehabilitation carried out in the ICU and emergency room are low intensity, intensive rehabilitation has not been found to be superior to rehabilitation with relatively low intensity (46, 47) . In addition, various types of cardiopulmonary rehabilitation have been documented as functional beneficial in the literature. For instance, prone positioning has been demonstrated to decrease mortality at day 28 (16.0 in the prone group vs. 32.8% in the supine group, p < 0.001) and day 90 (23.6 vs. 41.0%, p < 0.001) in patients with acute respiratory distress syndrome. Its application was strongly encouraged by several well-designed studies (27, 48) . Physiotherapy such as NMES-induced muscle contraction may serve as muscle pump to increase ejection capacity and improve both the venous return and muscle perfusion, consequently compensate cardiac function (49) . Moreover, ICUacquired weakness was frequently observed in the ICU and diaphragm dysfunction developed more often than limb muscle weakness (50) . Diaphragmatic weakness, occurs in as early as 18 h after mechanical ventilation, is attributed to proteolysisinduced muscle contractile dysfunction (51) . It was proven to be associated with a higher rate of mechanical ventilation weaning failure and prolonged length of mechanical ventilation (52) . Upon this condition, we also included electrical stimulation of phrenic nerve to minimize the reduction of diaphragm atrophy and strength over time, possibly contributing to speed up respiratory functional recovery and subsequently leading to increased rate of ECMO weaning and shortened length of ECMO therapy (53) (54) (55) . Taken together, it is reasonable to hypothesize that our protocolized cardiopulmonary rehabilitation may contribute to internal pathophysiological changes (e.g., cardiac output and maximal oxygen uptake) and spread it to external clinical outcomes (e.g., earlier weaning of ECMO and increased rated of ECMO weaning).

Additional important considerations, which we addressed when preparing the CaRe-ECMO trial protocol, were the following. First, the current trial is consisting of a RCT part followed by an open-label cohort part. According to our clinical experience and retrospective data analysis, the median length of ECMO weaning varied ∼from 7 to 9 days in all the types of ECMO-supported patients. The design rationale of the RCT part is to power the primary outcome, while the following open-label cohort part is dedicated to benefit patients who do not respond to one cycle of cardiopulmonary rehabilitation. This action may impair the effects of RCT on long-term outcome observation; however, it is hypothesized to provide additional opportunity for those who are probably benefitted from active intervention (56) . Second, a critical concern of the CaRe-ECMO trial design is the uncertainty of the effect size of the proposed interventions. Therefore, our attention on primary outcome selection has been shifted from the exact ECMO weaning to ready for ECMO weaning. If any significant results would be introduced in terms of earlier ready for ECMO weaning or increased rate of ready for ECMO weaning due to our proposed interventions, then it may satisfy the preliminary requirements when extending its effects to more consolidated outcomes (e.g., rate of ECMO weaning). To compensate the aforementioned risks, we introduce several evidence-based checklists to ensure the standardized definition and evaluation of ECMO or mechanical ventilation weaning (Tables 5-7) and to maximally avoid potential performance bias. Third, functional outcomes are essential to the longterm recovery; therefore, CPC index, ADL score, HRQoL score, and diaphragmatic thickness and mobility will be consecutively collected. In case when primary outcome of the CaRe-ECMO trial does not show a statistically significant difference, future trials may consider to analyze our secondary clinical and functional outcomes.

To sum up, the currently proposed CaRe-ECMO trial is a pragmatic, multidisciplinary, randomized controlled, parallel group, clinical trial, designed to answer the question whether cardiopulmonary rehabilitation can facilitate weaning of ECMO. Should the implementation of the CaRe-ECMO program result in superior primary and secondary outcomes as compared to the controls, the CaRe-ECMO trial will offer an innovative treatment option for ECMO-supported patients and meaningfully impact the standard care in ECMO therapy.

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

The studies involving human participants were reviewed and approved by the First Affiliated Hospital of Nanjing Medical University (Reference number of 2021-SR-416). The patients/participants provided their written informed consent to participate in this study.

XL, JZ, XC, YZ, and HS conceived the design of the trial, prepared and drafted the study protocol, and planned the statistical analysis. XL and JZ contributed to critical revision of the protocol, training of medical staff, and coordinating the trial. XC will conduct the eligibility screening for trial enrollment. YC, DP, LW, XZ, and SW are responsible for cardiopulmonary rehabilitation delivery. YM, JL, DH, FS, WL, GZ, and HZ are the clinical members of our ECMO therapy group and will be responsible for the medical care for ECMOsupported patients. YG is the leading nurse in the emergency room and will be responsible for coordination of providing nursing care for ECMO-supported patients. YZ and HS are responsible for data management and the communication with the DSMC. ZZ and BL are responsible for data acquisition and assist trial coordination. All the authors read and contributed intellectually important content and approved the final version of the manuscript. 

Extracorporeal membrane oxygenation (ECMO) for critically ill adults in the emergency department: history, current applications, and future directions

Extracorporeal life support for adults with acute respiratory distress syndrome

Bench-to-bedside review: mobilizing patients in the intensive care unit-from pathophysiology to clinical trials

Safety and feasibility of early physical therapy for patients on extracorporeal membrane oxygenator: university of maryland medical center experience

Physiotherapy for adult patients with critical illness: recommendations of the European respiratory society and European society of intensive care medicine task force on physiotherapy for critically ill patients

Enhanced Recovery After Critical Illness Programme G. Physical rehabilitation interventions for adult patients during critical illness: an overview of systematic reviews

Early mobilization during ECMO for cardiopulmonary failure in adults: factors associated with intensity of treatment

Early mobilization of patients receiving extracorporeal membrane oxygenation: a retrospective cohort study

Comparison of exercise intensity during four early rehabilitation techniques in sedated and ventilated patients in ICU: a randomised cross-over trial

Duration of veno-arterial extracorporeal life support (VA ECMO) and outcome: an analysis of the extracorporeal life support organization (ELSO) registry. Crit Care

Association of hospital-level volume of extracorporeal membrane oxygenation cases and mortality. Analysis of the extracorporeal life support organization registry

Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial

Update on weaning from veno-arterial extracorporeal membrane oxygenation

Safety and feasibility of a protocolized daily assessment of readiness for liberation from venovenous extracorporeal membrane oxygenation

Improving the reporting of pragmatic trials: an extension of the CONSORT statement

CONSORT statement for randomized trials of nonpharmacologic treatments: a 2017 update and a CONSORT extension for nonpharmacologic trial abstracts

World medical association declaration of Helsinki: ethical principles for medical research involving human subjects

Intensive care physiotherapy during extracorporeal membrane oxygenation for acute respiratory distress syndrome

Venoarterial ECMO for adults: JACC scientific expert panel

Management of adult patients supported with venovenous extracorporeal membrane oxygenation (VV ECMO): guideline from the extracorporeal life support organization (ELSO)

Allocation concealment in randomised trials: defending against deciphering

Feasibility and safety of early physical therapy and active mobilization for patients on extracorporeal membrane oxygenation

Early rehabilitation after lung transplantation with extracorporeal membrane oxygenation (ECMO) of COVID-19 patient: a case report

Diaphragm function in acute respiratory failure and the potential role of phrenic nerve stimulation

Related factors to semirecumbent position compliance and pressure ulcers in patients with invasive mechanical ventilation: an observational study (CAPCRI study)

Effect of care bundles in the nursing of severe pneumonia

Extracorporeal membrane oxygenation management: techniques to liberate from extracorporeal membrane oxygenation and manage post-intensive care unit issues

Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis

Official executive summary of an american thoracic society/american college of chest physicians clinical practice guideline: liberation from mechanical ventilation in critically ill adults

Quality of life and longterm mortality among survivors of extracorporeal membrane oxygenation: a nationwide cohort study in South Korea

Long-term health-related quality of life of adult patients treated with extracorporeal membrane oxygenation (ECMO): an integrative review

Sonographic evaluation of the diaphragm in critically ill patients. Technique and clinical applications

Neurological outcome after extracorporeal cardiopulmonary resuscitation for in-hospital cardiac arrest: a systematic review and metaanalysis

Long-Term outcomes after extracorporeal life support for acute respiratory failure

Improvement in patient-reported outcomes after lung transplantation is not impacted by the use of extracorporeal membrane oxygenation as a bridge to transplantation

A proposed charter for clinical trial data monitoring committees: helping them to do their job well

Mortality and costs following extracorporeal membrane oxygenation in critically ill adults: a population-based cohort study

Per-Protocol, intention-to-treat, and complier average causal effects analyses in randomized controlled trials: linking evidence to practice

Incorporating sampling weights into robust estimation of cox proportional hazards regression model, with illustration in the multiethnic study of atherosclerosis

Multilevel and Longitudinal Modeling Using Stata

The effect of early cardiopulmonary rehabilitation on the outcomes of intensive care unit survivors

Awake extracorporeal membrane oxygenation for acute respiratory distress syndrome: which clinical issues should be taken into consideration

Physical rehabilitation in the awake patient receiving extracorporeal circulatory or gas exchange support

Active rehabilitation and physical therapy during extracorporeal membrane oxygenation while awaiting lung transplantation: a practical approach

Standardized rehabilitation and hospital length of stay among patients with acute respiratory failure: a randomized clinical trial

A randomized trial of an intensive physical therapy program for patients with acute respiratory failure

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome

The influence of physical activity on chronic venous insufficiency of the lower limbs

Coexistence and impact of limb muscle and diaphragm weakness at time of liberation from mechanical ventilation in medical intensive care unit patients

Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans

Diaphragm dysfunction assessed by ultrasonography: influence on weaning from mechanical ventilation

Rapidly progressive diaphragmatic weakness and injury during mechanical ventilation in humans

Initial Assessment of the percutaneous electrical phrenic nerve stimulation system in patients on mechanical ventilation

Can phrenic stimulation protect the diaphragm from mechanical ventilationinduced damage?

Design, objectives, execution and reporting of published open-label extension studies

This trial was funded by the Nanjing Municipal Science and Technology Bureau (Grant No. 2019060002) and the National Natural Science Foundation of China (Grant Nos. 81772441, 81902288, and 82072546).

We greatly appreciate professionals in the CaRe-ECMO Trial Collaboration Group for their contribution for drafting the trial protocol and their future efforts to be donated to the trial conduction.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.Copyright © 2022 Zheng, Sun, Mei, Gao, Lv, Pan, Wang, Zhang, Hu, Sun, Li, Zhang, Zhang, Chen, Wang, Zhang, Li, Chen, Zhang and Lu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.